Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018

Abstract

IntroductionPrescription patterns of antidiabetic drugs in the period from 2012 to 2018 were investigated based on the Diabetes Registry Tyrol. To validate the findings, we compared the numbers with trends of different national registries conducted in a comparable period of time.Research design and methodsMedication data, prescription patterns, age groups, antidiabetic therapies and quality parameters (hemoglobin A1c, body mass index, complications) of 10 875 patients with type 2 diabetes from 2012 to 2018 were retrospectively assessed and descriptively analyzed. The changes were assessed using a time series analysis with linear regression and prescription trends were plotted over time.ResultsSodium/glucose cotransporter 2 inhibitors (SGLT-2i) showed a significant increase in prescription from 2012 to 2018 (p<0.001), as well as metformin (p=0.002), gliptins (p=0.013) and glucagon-like peptide-1 agonists (GLP-1a) (p=0.017). Significant reduction in sulfonylurea prescriptions (p<0.001) was observed. Metformin was the most frequently prescribed antidiabetic drug (51.3%), followed by insulin/analogs (34.6%), gliptins (28.2%), SGLT-2i (11.7%), sulfonylurea (9.1%), glitazones (3.7%), GLP-1a (2.8%) and glucosidase inhibitors (0.4%).ConclusionsIn this long-term, real-world study on prescription changes in the Diabetes Registry Tyrol, we observed significant increase in SGLT-2i, metformin, gliptins and GLP-1a prescriptions. In contrast prescriptions for sulfonylureas declined significantly. Changes were consistent over the years 2012–2018. Changes in prescription patterns occurred even before the publication of international and national guidelines. Thus, physicians change their prescription practice not only based on published guidelines, but even earlier on publication of cardiovascular outcome trials.

Therapeutic Potential of Butyrate for Treatment of Type 2 Diabetes

“…Although lifestyle interventions (including diet, exercise and weight loss) are the first option for managing T2D, patients are often prescribed medications. A variety of drugs are already available, but side effects (such as pancreatitis and gastrointestinal complications) ( 2 ), and lifelong dependency on drugs entail a significant burden on the patients and on the healthcare system globally. Therefore, novel individualized therapies are being developed, focused on safety and personalized management of T2D.…”

Antioxidants Isolated from Elaeagnus umbellata (Thunb.) Protect against Bacterial Infections and Diabetes in Streptozotocin-Induced Diabetic Rat Model

“…The only way to control T2DM is the use of proper diet, insulin, antidiabetic medications; thiozolidinediones, biguanides, sulfonylureas (glibenclamide, glimepiride), using specific enzyme inhibitors like acarbose and miglitol to reduce demands for insulin. Mostly antidiabetic medications have been isolated from plants sources that reinstate insulin production and hinder the intestinal glucose absorption [ 7 ].…”

Dipeptidyl Peptidase-4 Inhibitors Reduced Long-term Cardiovascular Risk in Japanese Diabetic Patients After Percutaneous Coronary Intervention via Insulin-like Growth Factor-1 Axis: A 10-year Follow-up Study

“…Appropriate glycemic control in combination with multifactorial risk control is thus essential in order to avoid macrovascular complications that can lead to critical consequences in diabetic patients. Among multiple lines of anti-diabetic medications, dipeptidyl peptidase-4 inhibitors (DPP4i) are a major antidiabetic agent class in the United States [3], European Union [4,5] and Japan [6]. Although accumulated experimental evidence has suggested an atheroprotective effects of DPP4 inhibition [7][8][9], previous major large-scale cardiovascular outcome trials (CVOTs) of DPP4i which primarily aimed to establish their non-inferiority compared to conventional anti-diabetic therapy, have not demonstrated a clear bene t with respect to improving outcomes in populations which mainly consisted of diabetic individuals with a history of CV disease (secondary prevention) [10][11][12][13].…”